Obermatt
See Similar Stocks →

Bicara Therapeutics

NMQ:BCAX · US0554771032
BiotechnologySmall

360

43
Medium confidence — indicative
Profit price46
Cash yield1
Sales & asset price46
Return on Capital48
Cash Return on Capital53
Return on Equity65
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth15
Long-Term EPS Growth18
Reinvestment82
Price momentum64
Debt load97
Refinancing45
Debt Payback1
Liquidity31
Analyst ratings11
Opinion Changes81
Price Target Upside38
Market mood41
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Bicara Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2018
Employees100
Websitebicara.com
ISINUS0554771032
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOncologyBiopharmaBiotechnologyTherapeutics

Description

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company has built a platform designed to facilitate the development of bifunctional…

Analysis

Middle-of-the-road

Bicara Therapeutics Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Bicara Therapeutics with its peers
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ALX Oncology Holdings
NSQ:ALXO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Castle Biosciences
NMQ:CSTL
10
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Nuvalent
NSQ:NUVL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →